Highest-materiality recent filing
Tenet Healthcare shareholders elect all 12 director nominees, approve say-on-pay, ratify auditor
All 12 director nominees elected; Saumya Sutaria received 72.3M for, 2.0M against, 76.9K abstain.
Tenet Q1 GAAP EPS $8.01, adj EPS $4.82 beats; Ambulatory EBITDA up 6.1%
Net income available to common shareholders $702M ($8.01 diluted EPS); adjusted diluted EPS $4.82 vs $4.36 YoY.
Tenet Healthcare CIO Paola Arbour to retire Dec 31, 2026; part-time transition through April 2028
EVP and CIO Arbour retires from executive role Dec 31, 2026, stays part-time as non-executive through April 1, 2028 at $820/week.
Tenet Healthcare appoints J. Michael Grooms as new Controller, Principal Accounting Officer
Retirement date of principal accounting officer R. Scott Ramsey changed to April 30, 2026; Ramsey to stay part-time through March 2028.
Tenet Q4 2025 adjusted EPS $4.70, up 36.6% YoY; FY2026 EBITDA guidance $4.485-$4.785B
Q4 net income $371M ($4.22 diluted EPS); adjusted EPS $4.70 vs $3.44 YoY; revenue $5.527B (+9% YoY).
Tenet announces $1.9B CommonSpirit deal; 2025 Adj. EBITDA at upper end of guidance
CommonSpirit to pay Tenet $1.9B over 3 years; Tenet redeems CommonSpirit's 23.8% Conifer equity for $540M.
Director Stephen H. Rusckowski resigns from Tenet Healthcare board
Stephen H. Rusckowski resigned from the Board effective November 21, 2025.
Tenet issues $2.25B in notes to refinance near-term debt maturities
Issued $1.5B of 5.500% senior secured first lien notes due 2032 and $750M of 6.000% senior notes due 2033.
Tenet enters $1.9B ABL revolving credit facility maturing 2030
New $1.9B senior secured revolving credit facility with $200M letter-of-credit sub-facility.
Tenet Healthcare prices $2.25B notes offering; upsized senior notes to 6.00% due 2033
Offering: $1.5B 5.500% first lien notes due 2032 and $0.75B 6.000% senior notes due 2033 (upsized from $0.5B).
Tenet Q3 adjusted EPS $3.70 beats $2.93 YoY; raises FY2025 EBITDA outlook
Net income $342M ($3.86 diluted); adjusted EPS $3.70, up 26.3% YoY from $2.93.
Tenet Q2 adjusted EPS $4.02 (+74% YoY); raises FY 2025 EBITDA outlook to $4.40-$4.54B
Q2 2025 net income $288M, $3.14 diluted EPS; adjusted diluted EPS $4.02 vs $2.31 in Q2 2024.
Tenet Healthcare promotes Lisa Y. Foo to Chief Operating Officer (newly created role)
Lisa Y. Foo named COO effective May 30, 2025; position is newly created.
Tenet Healthcare shareholders elect all 13 directors, approve say-on-pay
All 13 director nominees elected with strong support; Saumya Sutaria received 75.1M for, 3.2M against.
Net income available to common shareholders $406M ($4.27 diluted) vs $2.151B in Q1 2024 (prior year included $2.5B divestiture gain).
Tenet Q4 EPS $3.32 (adj. $3.44); FY2025 adj. EBITDA guidance $3.975-4.175B
Q4 net income $318M ($3.32 diluted); adjusted EPS $3.44 vs $2.68 year ago.
Base salary $1.5M; target annual bonus at least 200% of base ($3M).
Tenet Q3 adj. EPS $2.93 beats; raises FY24 EBITDA outlook to $3.9B-$4.0B
Q3 net income $472M ($4.89 diluted) includes $2.16 gain from hospital divestiture; adj. EPS $2.93.
Tenet to sell 70% stake in five Alabama hospitals to Orlando Health for $910M cash
Sale price $910M cash; after-tax proceeds ~$790M; pre-tax book gain ~$375M.
Tenet Q2 Net Income $259M, Adj EPS $2.31; Raises FY 2024 EBITDA, FCF Outlook
Q2 net income $259M ($2.64 diluted EPS), up from $123M ($1.15) YoY; adjusted EPS $2.31.
All 13 director nominees elected; votes for ranged from 78.4M to 81.2M.
Tenet Q1 adj EPS $3.22 beats; revenue $5.37B; raises FY2024 EBITDA outlook to $3.5-3.7B
Q1 net income $2.15B ($21.38 diluted) includes $1.86B after-tax gain from hospital sales; adjusted diluted EPS $3.22.
Tenet Healthcare completes sale of six California hospitals to UCI Health and Adventist Health
Four Orange County and LA County hospitals sold to UCI Health: Fountain Valley Regional, Lakewood Regional Medical Center, Los Alamitos Medical Center, Placentia-Linda Hospital.
Tenet sells two California hospitals for $550M cash; Conifer to partner with Adventist Health
Sale of Sierra Vista Regional Medical Center and Twin Cities Community Hospital for $550M (after-tax ~$450M).
Tenet calls for full redemption of $2.1B 4.875% Senior Secured Notes due 2026
All $2.1 billion aggregate principal of 4.875% Senior Secured First Lien Notes due 2026 called for redemption.
Tenet Q4 net income $244M, adj EBITDA $1.012B (+12.8% YoY); 2024 outlook $3.285-3.485B adj EBITDA
Q4 GAAP diluted EPS $2.30 vs $0.92 YoY; adjusted diluted EPS $2.68 vs $1.96.
Completed sale of three SC hospitals (Coastal Carolina, Hilton Head, East Cooper) to Novant for $2.4B cash.
Completed sale of three South Carolina hospitals plus affiliated physician practices and other operations to affiliates of Novant Health for $2.4B cash (subject to customary adjustments).
Tenet Healthcare appoints Vineeta Agarwala to Board of Directors, effective Dec 11, 2023
Board size increased from 12 to 13 upon Dr. Agarwala's appointment.
Tenet sells three SC hospitals to Novant for $2.4B cash; expects ~$1.6B pre-tax gain
Sale includes Coastal Carolina, East Cooper Medical, Hilton Head hospitals and related operations.
Tenet Q3 adj EPS $1.44; raises FY 2023 EBITDA outlook to $3.365-3.465B
Net income $101M ($0.94 GAAP); adjusted diluted EPS $1.44 vs $1.42 YoY.
Tenet extends $200M LC facility to March 2027, switches to SOFR
Extended letter of credit facility maturity from Sept 2024 to March 2027.
Tenet CFO Cancelmi to stay part-time through Apr 2025 at $750/week under transition agreement
CFO Daniel Cancelmi signed transition agreement Aug 9, 2023; full-time employment ends Dec 31, 2023.
Tenet Healthcare appoints former U.S. Senator Roy Blunt to Board of Directors
Senator Roy Blunt appointed to Tenet's Board effective August 9, 2023; Board expands from 11 to 12 members.
Tenet Q2 net income $123M ($1.15/diluted); raises FY23 EBITDA view to $3.31-3.46B
Net income from continuing ops $123M ($1.15/diluted); adjusted EPS $1.44; revenue $5.08B, up from $4.64B YoY.
Tenet names Sun Park as CFO effective Jan 2024; replaces retiring Dan Cancelmi
Sun Park appointed EVP & CFO effective Jan 1, 2024; will serve as EVP from July 11, 2023.
Tenet Healthcare appoints Stephen H. Rusckowski to Board of Directors
Stephen H. Rusckowski appointed to Tenet's Board, effective May 25, 2023.
Tenet Healthcare annual meeting: all director nominees elected, say-on-pay passes
All 10 director nominees elected with majority FOR votes; highest was Saumya Sutaria with 85.7M FOR.
Tenet Healthcare issues $1.35B of 6.750% senior secured notes due 2031 to refinance near-term debt
Issued $1,350,000,000 aggregate principal of 6.750% senior secured first lien notes due 2031.
Tenet prices $1.35B 6.75% secured notes due 2031 to refinance 2024 debt
Issued $1.35B of 6.750% senior secured first lien notes maturing May 15, 2031; closing expected May 16.
Tenet Q1 adj EPS $1.42 rev $5.02B; raises FY23 EBITDA outlook to $3.21-3.41B
Q1 net income from continuing ops $143M ($1.32 dil EPS); adj diluted EPS $1.42 vs $1.90 YoY.
Tenet Q4 net income $102M ($0.92 diluted EPS), FY2023 Adj. EBITDA guidance $3.16B-$3.36B
Q4 2022 net income from continuing ops $102M ($0.92 diluted EPS) vs $250M ($2.30) a year ago; adjusted diluted EPS $1.96 vs $2.70.
Tenet expects FY22 Adj. EBITDA slightly above $3.425B midpoint; CFO to retire
Prelim FY22 Adj. EBITDA (ex-pandemic grants) slightly above $3.425B guidance midpoint.
Tenet Q3 net income $131M, adj EPS $1.44; announces $1B buyback; FY22 EBITDA outlook narrowed
Q3 net income from continuing ops $131M ($1.16 diluted EPS); adjusted diluted EPS $1.44.
Executive Chairman Rittenmeyer resigns due to health; J. Robert Kerrey appointed Chairman
Ronald A. Rittenmeyer resigned as Executive Chairman and Board member effective Oct 1, 2022 due to personal health reasons.
Tenet Q2 net income falls 68% to $38M; adjusted EBITDA up 1% to $843M
Net income from continuing ops $38M ($0.35 EPS) vs $120M ($1.11) in Q2'21.
Tenet issues $2B of 6.125% senior secured notes due 2030 to redeem 2023 notes
$2B aggregate principal of 6.125% senior secured first lien notes due 2030 issued.
Tenet Healthcare Prices $2.0 Billion Senior Secured Notes Offering to Redeem 2023 Notes
Tenet Healthcare upsized its private offering of senior secured first lien notes to $2.0 billion, priced at 6.125% due 2030.
Tenet shareholders elect 11 directors, approve say-on-pay and stock plan amendment
All 11 director nominees elected with majority support; Rittenmeyer received 86.7M for, 1.3M against.
Tenet Q1 adj. EBITDA $882M (ex. grants) beats outlook; net income $139M; retired $824M debt
Net income from continuing ops $139M vs $97M YoY; adj. diluted EPS $1.93 vs $1.30.
On May 30, 2025 , Lisa Y. Foo was promoted to Chief Operating Officer of Tenet Healthcare Corporation (the “Company”), a newly created position within the Company, effective immediately.
On December 11, 2023 , the Board of Directors (the “Board”) of Tenet Healthcare Corporation (the “Company”) appointed Vineeta Agarwala to the Board, effective immediately.
On January 19, 2023 , the Company filed the Report to disclose that Daniel Cancelmi, Executive Vice President & Chief Financial Officer, had announced his retirement from the Company, effective December 31, 2023.
On August 9, 2023 , the Board of Directors (the “Board”) of Tenet Healthcare Corporation (the “Company”) appointed Senator Roy Blunt to the Board, effective immediately.
Mr. Park will succeed Daniel Cancelmi, current Executive Vice President & Chief Financial Officer, whose previously announced retirement becomes effective on December 31, 2023.
Sun Park, age 47, has been appointed Executive Vice President and Chief Financial Officer of the Company, effective January 1, 2024.
On May 25, 2023 , the Board of Directors (the “Board”) of Tenet Healthcare Corporation (the “Company”) appointed Stephen H. Rusckowski to the Board, effective immediately.
Daniel Cancelmi, Executive Vice President & Chief Financial Officer, has announced his retirement from the Company, effective December 31, 2023.
The Board appointed J. Robert Kerrey as Chairman of the Board effective as of October 1, 2022, and reduced the number of authorized directors on the Board to ten.
Ronald A. Rittenmeyer, who had served as the Executive Chairman of Tenet Healthcare Corporation (the “Company”) and as a member of the board of directors of the Company (the “Board”), resigned due to personal health reasons effective as of October 1, 2022.
the Amendment provides that, between January 1, 2024 and December 31, 2025 when Mr. Rittenmeyer will serve as a senior advisor to the Chief Executive Officer and the Company’s board of directors
Ronald A. Rittenmeyer will transition from Chief Executive Officer of the Company and continue as the Executive Chairman of the Company and the Company’s board of directors (the “ Board ”) through 2022
Max materiality 0.85 · Median 0.70 · Most common event earnings